MIAMI BIOTECH STARTUP AEGLE THERAPEUTICS DRAWS $4M INVESTMENT ROUND

    0
    69

    Aegle Therapeutics, a biotech startup that sprouted from IP licensed from the University of Miami, now will proceed to its first clinical trial, helped by a $4 million round led by Boca Raton-based New World Angels. Orlando-based DeepWork Capital, existing investor Ocean Azul Partners of Coral Gables as well as Tellus BioVentures and DEFTA Healthcare  Technologies participated in the round.

    Aegle, led by CEO Shelley Hartman and based at CIC Miami, is developing a stem cell therapy platform technology initially to treat a rare pediatric skin blistering disorder called Dystrophic epidermolysis bullosa, as well as severe dermatological conditions including burns.